The Supreme Prosecutors’ Office Special Investigation Division (SID) yesterday closed its investigation into Yu Chang Biologics Co (宇昌生技股份有限公司), now known as TaiMed Biologics Inc (中裕新藥股份有限公司), clearing former Democratic Progressive Party (DPP) chairperson Tsai Ing-wen (蔡英文) of any wrongdoing.
The SID launched its investigation during the presidential campaign after Chinese Nationalist Party (KMT) lawmakers accused Tsai of manipulating investments by the National Development Fund (NDF) in TaiMed when she was vice premier in 2007. Tsai served as chairperson of the biotech company for several months after she stepped down as vice premier in May 2007.
The SID said Tsai did not embezzle any money in the case or abuse any funds. All the money in the National Development Fund’s investment in TaiMed was legal and clear, it said.
Photo: CNA
The SID investigated Taiwan Biopharmaceuticals Co (南華生技), which applied for National Development Fund support in 2005 and 2007, and TaiMed Biotech Fund, which applied for funding in 2007 and 2008.
Taiwan Biopharmaceuticals was to be a pharmaceutical company founded in Taiwan by Nancy Chang (唐南珊), chairperson of Tanox — a US-based biopharmaceutical company — and then-Euroc Venture Capital Co chairman Kao Yu-jen (高育仁) for the research and development of a drug known as TNX-355.
TNX-355 is an anti-AIDS drug that may prevent HIV from breaching the immune system.
The SID investigation clarified why the National Development Fund refused Taiwan Biopharmaceuticals’ TNX-355 funding request, but provided funding to Yu Chang, which was importing and developing a similar drug from the US drug giant Genentech and later acquired Tanox in 2007.
The SID said there was no evidence that the National Development Fund’s decision resulted from external factors and there was no evidence that senior government officials lobbied for TaiMed.
Documents showed the fund’s decision not to provide support to Taiwan Biopharmaceuticals Co was because Tanox had been acquired by Genentech, and Taiwan Biopharmaceuticals Co did not clearly explain its future technology sources and the company’s development structure to the fund, the SID said.
The SID said that although both TaiMed and Taiwan Biopharmaceuticals Co planned to build plants and manufacture products in Taiwan, Taiwan Biopharmaceuticals Co’s plan was to manufacture 80 percent of Tanox’s orders, but TaiMed’s proposal was that TaiMed and Genentech cooperate to develop TNX-355 and that the new drug, if developed successfully, would be manufactured in Taiwan.
The SID said the Tsai family invested in TaiMed using their own money and that all the funding was clean.
The SID said it interviewed more than 30 people during the investigation, including former premier Su Tseng-chang (蘇貞昌), former Council for Economic Planning and Development (CEPD) chairpersons Ho Mei-yueh (何美玥) and Hu Sheng-cheng (胡勝正), and Yu Chang funders David Ho (何大一), an AIDS expert, and Chen Lan-bo (陳良博), a Harvard University professor.
The SID said Hu, who may have violated laws regarding the private-public boundary, was sent to the Taipei District Prosecutors’ Office for investigation.
Hu served as chairperson of TaiMed after leaving his post at the council.
The SID also sent former National Development Fund deputy executive director James Ho (何俊輝) to the Control Yuan for investigation because it said he had inappropriately discussed Yu Chang’s proposal at Tsai’s residence and office.
In a press release, Tsai said she has always been honest about her role and involvement in Yu Chang Biologics, which she said was a collaboration between the administrative and legislative branch to promote development of Taiwan’s biotechnology industry.
However, she said the KMT administration used the case as a political tool during the presidential campaign, a move that not only tainted the reputation of several renowned scientists, but also hurt the development of the sector.
“While the [SID’s] decision has proven the innocence of the people involved, it would be very difficult for me to say that I’m happy with the results,” Tsai said.
Tsai said she was not surprised by the findings, adding that she hoped the case would be an example for elections in the future.
“We hope the mud-slinging tactics will stop right here and the national leader will no longer employ government agencies for political gain,” Tsai said.
Additional reporting by staff reporter Chris Wang
A Ministry of Foreign Affairs official yesterday said that a delegation that visited China for an APEC meeting did not receive any kind of treatment that downgraded Taiwan’s sovereignty. Department of International Organizations Director-General Jonathan Sun (孫儉元) said that he and a group of ministry officials visited Shenzhen, China, to attend the APEC Informal Senior Officials’ Meeting last month. The trip went “smoothly and safely” for all Taiwanese delegates, as the Chinese side arranged the trip in accordance with long-standing practices, Sun said at the ministry’s weekly briefing. The Taiwanese group did not encounter any political suppression, he said. Sun made the remarks when
The Taiwanese passport ranked 33rd in a global listing of passports by convenience this month, rising three places from last month’s ranking, but matching its position in January last year. The Henley Passport Index, an international ranking of passports by the number of designations its holder can travel to without a visa, showed that the Taiwan passport enables holders to travel to 139 countries and territories without a visa. Singapore’s passport was ranked the most powerful with visa-free access to 192 destinations out of 227, according to the index published on Tuesday by UK-based migration investment consultancy firm Henley and Partners. Japan’s and
BROAD AGREEMENT: The two are nearing a trade deal to reduce Taiwan’s tariff to 15% and a commitment for TSMC to build five more fabs, a ‘New York Times’ report said Taiwan and the US have reached a broad consensus on a trade deal, the Executive Yuan’s Office of Trade Negotiations said yesterday, after a report said that Washington is set to reduce Taiwan’s tariff rate to 15 percent. The New York Times on Monday reported that the two nations are nearing a trade deal to reduce Taiwan’s tariff rate to 15 percent and commit Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) to building at least five more facilities in the US. “The agreement, which has been under negotiation for months, is being legally scrubbed and could be announced this month,” the paper said,
MIXED SOURCING: While Taiwan is expanding domestic production, it also sources munitions overseas, as some, like M855 rounds, are cheaper than locally made ones Taiwan and the US plan to jointly produce 155mm artillery shells, as the munition is in high demand due to the Ukraine-Russia war and should be useful in Taiwan’s self-defense, Armaments Bureau Director-General Lieutenant General Lin Wen-hsiang (林文祥) told lawmakers in Taipei yesterday. Lin was responding to questions about Taiwan’s partnership with allies in producing munitions at a meeting of the legislature’s Foreign Affairs and National Defense Committee. Given the intense demand for 155mm artillery shells in Ukraine’s defense against the Russian invasion, and in light of Taiwan’s own defensive needs, Taipei and Washington plan to jointly produce 155mm shells, said Lin,
RSS